CDT Equity Partners With QIMA Life Sciences To Develop Several Of The Company's Autoimmune Skin Disease Assets, Including Novel Tapinarof Combinations In Psoriasis And Vitiligo

CDT Equity Partners has partnered with QIMA Life Sciences to develop autoimmune skin disease assets, focusing on novel combinations of tapinarof (VTAMA®) for psoriasis and vitiligo. Tapinarof is currently approved for plaque psoriasis and atopic dermatitis in the US and Japan, and CDT aims to enhance its efficacy through combination therapies. The global vitiligo drug market is projected to grow from approximately $2.6 billion in 2025 to $6.6 billion by 2030, highlighting a significant opportunity for new therapies in this area.